Karo Bio USA, Inc.

STOCKHOLM, Sept. 26, 2022 /PRNewswire/ -- Karo Intressenter AB[1] (" Karo Intressenter") announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (" Karo Pharma" or the " Company") to acquire the shares in Karo Pharma not already held by Karo Intressenter at a price of SEK 60 per share (the " Offer"). On 19 September 2022, Karo Intressenter announced the outcome of the Offer, that they completed the Offer and that Karo Intressenter thereby, at the time of the publication of the announcement, controlled in total approximately 93.7 percent of the total number of shares and votes in Karo Pharma. At the same time, Karo Intressenter announced that the acceptance period was extended until 7 October 2022. Karo Intressenter has initiated compulsory redemption of the remaining shares in Karo Pharma. Karo Intressenter, holding approximately 93.7 percent of the shares and votes in Karo Pharma, has initiated compulsory redemption of the remaining shares in Karo Pharma. Karo Pharma has today notified the minority shareholders that compulsory redemption has been requested and that the minority shareholders will have the opportunity to, no later than two weeks from today's date, in writing report that they wish to bring their own action and state a joint arbitrator. If shareholders to which the redemption claim is directed at does not submit the name of a joint arbitrator within the prescribed time, the Board of Directors of Karo Pharma will file an application with the Swedish Companies Registration Office for appointment of a trustee. The trustee shall appoint a joint arbitrator for the minority shareholders and shall safeguard the interest of absent shareholders in the dispute. For further information, please contact: Christoffer Lorenzen, CEO, +46 73-501 76 20, [email protected] Jon Johnsson, CFO, +46 73-507 88 61, [email protected] The information was submitted for publication by the contact persons set out above, at 26 September CEST on 08:30 2022. About Karo Pharma Karo Pharma offers "Smart choices for everyday healthcare". We own and commercialize reliable original brands within prescription drugs and over-the-counter consumer products. Our products are available in over 90 countries with the core in Europe and the Nordics region. The headquarter of Karo Pharma is in Stockholm and the company is listed on Nasdaq First North Growth Market. Certified Adviser Erik Penser Bank AB is the Karo Pharma's Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email:[email protected]. [1] A Swedish private limited liability company (Sw. privat aktiebolag) controlled by EQT VIII, registered with the Swedish Companies Registration Office with corporate registration number 559160-9416. This information was brought to you by Cision The following files are available for download: SOURCE Karo Pharma

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Karo Bio (STO:KARO) THE JANUARY-MARCH PERIOD 2015 IN BRIEF · Net sales amounted to MSEK 0.4 (6.4) Help employers find you! Check out all the jobs and post your resume.

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Karo Bio announced today that it has been informed by its research partner, Wyeth Pharmaceuticals, a division of Wyeth, that development of LXR-623 has been discontinued. The compound had been in phase 1 testing for the treatment of atherosclerosis. While LXR-623 demonstrated efficacy on biomarkers for atherosclerosis, it had an unfavorable pro further development. Karo Bio and Wyeth remain committed to the research partnership and to advancing a new lead compound under the terms of the collaboration, which was recently extended until August 31, 2008. The collaboration between Karo Bio and Wyeth targets the Liver X Receptor (LXR), with the aim to develop new treatments for atherosclerosis. LXR regulates transport proteins, including ABCA1 and ABCG1, which promote reverse cholesterol transport (transport of cholesterol from peripheral tissues to the liver). Furthermore, it has been demonstrated that small molecular compounds that activate LXR have anti-atherogenic properties. "Unfortunately compounds do fail in the process but this is part of the development of pharmaceuticals. We remain optimistic about LXR as a target for treatment of atherosclerosis and for the prospects for new molecules for development. The learnings generated from the LXR-623 program will be valuable as additional potential compounds move forward. We have recently extended our collaboration with Wyeth and we are pleased with Wyeth's commitment to the program", says Per Olof Wallstrom, President of Karo Bio. Facts about Karo Bio Karo Bio is a drug discovery and development company specializing in nuclear receptors for the development of novel pharmaceuticals with focus on metabolic diseases. The company has expanded from being a drug discovery company by adding in-house preclinical and clinical development resources and competence for development of drugs to treat metabolic diseases. The company has a strong project portfolio with innovative molecules that primarily targets diseases such as diabetes, atherosclerosis and dyslipidemia. In all of these areas there are significant market opportunities and a growing need for new pharmaceuticals with new mechanisms of action. In addition to the proprietary projects Karo Bio has two strategic collaborations with international pharmaceutical companies and one biotech collaboration for development of innovative therapies for the treatment of common diseases. Karo Bio is listed on the OMX Nordic Exchange Stockholm AB since 1998 (Reuters: KARO.ST). This press release is also available online at: and This information was brought to you by Cision Contact: Per Olof Wallstrom President & Chief Executive Officer Telephone: +46 8 608 60 20 or Per Otteskog Senior Vice President Telephone: +46 8 608 60 18 Source: Karo Bio